If you can't see the fine print, it shares at least 3 Wall Street analysts have provided targets within the last 12 months.
In each case, their targets are suggesting MBRX to have more than triple-digit upside potential from its chart positioning at close on Thursday.
And with a $21.00 average target, MBRX may have a potential 700+% upside as of 4:00PM EST yesterday. -----
#3. MBRX Potential Catalyst - New Data Announced: Annamycin Extends Survival By 60+% In Preclinical Models.
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication
Significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems (p<0.001)
Significantly higher tumor and pancreatic tissue accumulation than doxorubicin (p<0.0001), providing a mechanistic basis for Annamycin’s activity where traditional anthracyclines have historically failed
Induced infiltration of CD8+ and CD4+ T cells, suggesting potential to convert immunologically “cold” pancreatic tumors into responders and supporting future combinations with checkpoint and KRAS inhibitors
Continues to demonstrate the absence of cardiotoxicity, a well-documented limitation of conventional anthracyclines such as doxorubicin
HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 highlighting the potential of its lead drug candidate, Annamycin, in pancreatic cancer. Access the poster here.
“We are highly encouraged by these results, which demonstrate compelling anti-tumor activity in pancreatic cancer models. Importantly, these findings are consistent with the effects we continue to observe with Annamycin in AML," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “This consistency across both hematologic and solid tumor settings reinforces our confidence in Annamycin’s underlying mechanism.”
“It is important to highlight that the clinical landscape continues to reflect the trend toward increased use of combination therapies, especially those that combine innovative targeted mechanisms with time-tested cytotoxic payloads. It’s in these settings that Annamycin’s potential may be at its greatest considering its lack of cardiotoxicity, greater tolerability and ability to avoid resistance mechanisms. We believe these data underscore Annamycin’s potential to expand into additional high-need cancer indications,” added Mr. Klemp.
...
Read the full article here. -----
#4. MBRX Potential Catalyst - A Key Milestone Notched As The Company Prepares For The Possibility Of A Defining Inflection Point.
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company History
Early Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient Population
Enrollment Accelerating Toward 90 Subject Threshold as Phase 3 Pathway Takes Shape
HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). This milestone triggers the final phase of preparation for the trial’s interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.
“We believe this upcoming data readout represents the most important milestone in our history to date,” said Walter Klemp, Chairman and CEO of Moleculin. “This is a critical achievement for Moleculin and, more importantly, for patients facing relapsed or refractory AML. Reaching the 45 subject mark brings us to the threshold of our first meaningful look at MIRACLE data. Based on what we believe to be encouraging blinded results announced in February, we believe we are building real momentum toward what could be a transformative outcome. Our Phase 2 AML MB-106 clinical trial generated greater efficacy than any drug ever approved for relapsed or refractory AML, and it contributed to the more than 100 patients treated to date without any associated cardiotoxicity. What remains now is to demonstrate that a larger Phase 3 trial can produce results that will support new drug approval. The upcoming unblinding of the first 45 subjects should be a strong indicator of that potential. A true next-generation anthracycline has long been sought by medical science and would rightly be considered a gamechanger, not just for AML but for a wide range of cancers. We now appear to be on the threshold of finding out whether this can become a reality.”
...
Read the full article here. -----
#5. MBRX Potential Catalyst - The Company Approaches The First Unblinding Of Data In Its Pivotal Phase 2B/3 “MIRACLE” Study Of Annamycin.
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response
Roughly 35% of the subjects treated to date represent ventoclax regimen failures
Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a “significant advancement” in AML treatment
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it is approaching the first unblinding of data in its pivotal Phase 2B/3 “MIRACLE” study of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML), having treated 35 subjects to date with another 11 in screening or identified. Additional subjects continue to be identified by site investigators. The targeted number for the first unblinding of data is 45 subjects with the Company believing it is on track to treat the 45th subject in Q1 2026 with unblinding of data thereafter. This update is as of February 10, 2026, as treatment, identification and recruitment are ongoing.
Additionally, the Company reports a preliminary composite complete remission (CRc) rate of 40% in the MIRACLE trial’s first 30 subjects treated and with blinded, preliminary efficacy data. This CRc rate is comprised of a complete remission (CR) rate of 30% and complete remission with partial hematological recovery (CRh) of 10%.
“The blinded efficacy rates we’re seeing in MIRACLE are exceptionally encouraging,” said Walter Klemp, Chairman and CEO of Moleculin. “And, of course, this includes the control arm of cytarabine plus placebo, which suggests that the Annamycin results should be better. Even with the control arm included, these preliminary, blinded results substantially outperform historical outcomes for CR with cytarabine alone and reinforce our expectations of what Annamycin can become in the treatment of R/R AML. Of particular note is that roughly 35% of the subjects treated to date are relapsed or refractory (R/R) from a venetoclax regimen, a subject population that is generally considered among the most challenging to address with 2nd line therapies. With the first unblinding now clearly in sight, we are entering what we believe is a transformational period for the Company.”
...
Read the full article here. -----
(Nasdaq: MBRX) Recap - 5 Potential Catalysts Lead The Way
#1. A Low Float May Be Establishing An Environment For Heightened Volatility Potential.
#2. An Average Analyst $21 Target Spells A Possible Triple-Digit Upside.
#3. New Data Announced: Annamycin Extends Survival By 60+% In Preclinical Models.
#4. A Key Milestone Notched As The Company Prepares For The Possibility Of A Defining Inflection Point.
#5. The Company Approaches The First Unblinding Of Data In Its Pivotal Phase 2B/3 “MIRACLE” Study Of Annamycin. -----
Coverage is officially underway on Moleculin Biotech, Inc. (Nasdaq: MBRX).
Be on the lookout for updates coming out soon. Talk again shortly.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
Sources: (1) Moleculin Biotech, Inc. (2024). Form 10-K for the fiscal year ended December 31, 2024.
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/08/2026 and ending on 05/08/2026 to publicly disseminate information about (MBRX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MBRX:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/mbrx-e3euw/#details |
